Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.

Maude SL.

Clin Adv Hematol Oncol. 2018 Oct;16(10):664-666. Review. No abstract available.

PMID:
30543595
2.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.

Nat Med. 2018 Oct;24(10):1499-1503. doi: 10.1038/s41591-018-0201-9. Epub 2018 Oct 1.

3.

Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.

Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Hamilton J, Awasthi R, Stein AM, Sickert D, Chakraborty A, Levine BL, June CH, Tomassian L, Shah SS, Leung M, Taran T, Wood PA, Maude SL.

Clin Cancer Res. 2018 Dec 15;24(24):6175-6184. doi: 10.1158/1078-0432.CCR-18-0758. Epub 2018 Sep 6.

PMID:
30190371
4.

Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.

Leahy AB, Elgarten CW, Grupp SA, Maude SL, Teachey DT.

Expert Rev Anticancer Ther. 2018 Oct;18(10):959-971. doi: 10.1080/14737140.2018.1512411. Review.

PMID:
30111196
5.

False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy.

Laetsch TW, Maude SL, Milone MC, Davis KL, Krueger J, Cardenas AM, Eldjerou LK, Keir CH, Wood PA, Grupp SA.

Blood. 2018 Jun 7;131(23):2596-2598. doi: 10.1182/blood-2017-12-822940. Epub 2018 Apr 18. No abstract available.

6.

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA.

N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.

7.

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.

Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT.

Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.

8.

New developments in immunotherapy for pediatric leukemia.

Foster JB, Maude SL.

Curr Opin Pediatr. 2018 Feb;30(1):25-29. doi: 10.1097/MOP.0000000000000572. Review.

PMID:
29176353
9.

CAR emissions: cytokines tell the story.

Maude SL.

Blood. 2017 Nov 23;130(21):2238-2240. doi: 10.1182/blood-2017-10-808592. No abstract available.

10.

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.

Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, Waldron E, Chakraborty A, Awasthi R, Levine BL, Melenhorst JJ, Grupp SA, June CH, Lacey SF.

Blood. 2017 Nov 23;130(21):2317-2325. doi: 10.1182/blood-2017-06-786129. Epub 2017 Sep 21.

11.

CART attack.

Pillai V, Maude SL.

Blood. 2017 Jul 13;130(2):229. doi: 10.1182/blood-2017-04-779009. No abstract available.

12.

Future directions in chimeric antigen receptor T cell therapy.

Maude SL.

Curr Opin Pediatr. 2017 Feb;29(1):27-33. doi: 10.1097/MOP.0000000000000436. Review.

PMID:
27841776
13.

Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma.

Yu H, Sotillo E, Harrington C, Wertheim G, Paessler M, Maude SL, Rheingold SR, Grupp SA, Thomas-Tikhonenko A, Pillai V.

Am J Hematol. 2017 Jan;92(1):E11-E13. doi: 10.1002/ajh.24594. Epub 2016 Nov 21. No abstract available.

14.

Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, Teachey DT.

Crit Care Med. 2017 Feb;45(2):e124-e131. doi: 10.1097/CCM.0000000000002053.

15.

Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.

Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, Obstfeld AE, Lacey SF, Melenhorst JJ, Nazimuddin F, Hwang WT, Maude SL, Wasik MA, Bagg A, Schuster S, Feldman MD, Porter DL, Grupp SA, June CH, Milone MC.

Blood. 2016 Jul 21;128(3):360-70. doi: 10.1182/blood-2016-01-694356. Epub 2016 May 10.

16.

CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.

Singh N, Frey NV, Grupp SA, Maude SL.

Curr Treat Options Oncol. 2016 Jun;17(6):28. doi: 10.1007/s11864-016-0406-4. Review.

PMID:
27098534
17.

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA.

Cancer Discov. 2016 Jun;6(6):664-79. doi: 10.1158/2159-8290.CD-16-0040. Epub 2016 Apr 13.

18.

Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.

Chen F, Teachey DT, Pequignot E, Frey N, Porter D, Maude SL, Grupp SA, June CH, Melenhorst JJ, Lacey SF.

J Immunol Methods. 2016 Jul;434:1-8. doi: 10.1016/j.jim.2016.03.005. Epub 2016 Apr 3.

19.

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A.

Cancer Discov. 2015 Dec;5(12):1282-95. doi: 10.1158/2159-8290.CD-15-1020. Epub 2015 Oct 29.

20.

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

Maude SL, Teachey DT, Porter DL, Grupp SA.

Blood. 2015 Jun 25;125(26):4017-23. doi: 10.1182/blood-2014-12-580068. Epub 2015 May 21. Review.

21.

Chimeric antigen receptor T-cell therapy for ALL.

Maude SL, Shpall EJ, Grupp SA.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):559-64. doi: 10.1182/asheducation-2014.1.559. Epub 2014 Nov 18. Review.

PMID:
25696911
22.

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, Grupp SA, Lock RB, Teachey DT.

Blood. 2015 Mar 12;125(11):1759-67. doi: 10.1182/blood-2014-06-580480. Epub 2015 Feb 2.

23.

Chimeric antigen receptor T cells for sustained remissions in leukemia.

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA.

N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222. Erratum in: N Engl J Med. 2016 Mar 10;374(10):998.

24.

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

Maude SL, Barrett D, Teachey DT, Grupp SA.

Cancer J. 2014 Mar-Apr;20(2):119-22. doi: 10.1097/PPO.0000000000000035. Review.

25.

Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States.

Maude SL, Fitzgerald JC, Fisher BT, Li Y, Huang YS, Torp K, Seif AE, Kavcic M, Walker DM, Leckerman KH, Kilbaugh TJ, Rheingold SR, Sung L, Zaoutis TE, Berg RA, Nadkarni VM, Thomas NJ, Aplenc R.

Pediatr Crit Care Med. 2014 Feb;15(2):112-20. doi: 10.1097/PCC.0000000000000042.

26.

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, Grupp SA.

Blood. 2013 Jun 27;121(26):5154-7. doi: 10.1182/blood-2013-02-485623. Epub 2013 May 15.

27.

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.

Maude SL, Tasian SK, Vincent T, Hall JW, Sheen C, Roberts KG, Seif AE, Barrett DM, Chen IM, Collins JR, Mullighan CG, Hunger SP, Harvey RC, Willman CL, Fridman JS, Loh ML, Grupp SA, Teachey DT.

Blood. 2012 Oct 25;120(17):3510-8. doi: 10.1182/blood-2012-03-415448. Epub 2012 Sep 6.

28.

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.

Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, Teachey DT, Maude SL, Tse K, Moore R, Jones S, Mungall K, Birol I, Edmonson MN, Hu Y, Buetow KE, Chen IM, Carroll WL, Wei L, Ma J, Kleppe M, Levine RL, Garcia-Manero G, Larsen E, Shah NP, Devidas M, Reaman G, Smith M, Paugh SW, Evans WE, Grupp SA, Jeha S, Pui CH, Gerhard DS, Downing JR, Willman CL, Loh M, Hunger SP, Marra MA, Mullighan CG.

Cancer Cell. 2012 Aug 14;22(2):153-66. doi: 10.1016/j.ccr.2012.06.005.

29.

Traffic safety for the cell: influence of cyclin-dependent kinase activity on genomic stability.

Enders GH, Maude SL.

Gene. 2006 Apr 12;371(1):1-6. Epub 2006 Feb 3. Review.

PMID:
16458456
30.

Supplemental Content

Loading ...
Support Center